Hybrid Coronary Revascularization: Insights Into Long-Term Clinical Outcomes From a Single-Center Experience

IF 1.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Ibrahim Gadelkarim, Nikhil Deshmukh, David Holzhey, Wolfgang Otto, Philipp Kiefer, Suzanne de Waha, Steffen Desch, Holger Thiele, Piroze Davierwala, Michael A. Borger, Alexander Verevkin
{"title":"Hybrid Coronary Revascularization: Insights Into Long-Term Clinical Outcomes From a Single-Center Experience","authors":"Ibrahim Gadelkarim,&nbsp;Nikhil Deshmukh,&nbsp;David Holzhey,&nbsp;Wolfgang Otto,&nbsp;Philipp Kiefer,&nbsp;Suzanne de Waha,&nbsp;Steffen Desch,&nbsp;Holger Thiele,&nbsp;Piroze Davierwala,&nbsp;Michael A. Borger,&nbsp;Alexander Verevkin","doi":"10.1155/jocs/3786314","DOIUrl":null,"url":null,"abstract":"<p><b>Background:</b> Hybrid coronary revascularization (HCR) combines minimally invasive direct coronary artery bypass (MIDCAB) to the left anterior descending artery (LAD) with percutaneous coronary intervention (PCI) for non-LAD lesions. HCR aims to balance the durability of surgical revascularization with the reduced invasiveness of PCI. This study evaluates 20 years of HCR experience at a single center, focusing on short- and long-term clinical outcomes.</p><p><b>Methods:</b> A retrospective analysis was conducted on 2969 patients who underwent MIDCAB between 1996 and 2020 at the Heart Center Leipzig. A total of 177 patients met the inclusion criteria, defined as MIDCAB followed or preceded by PCI within 100 days. Exclusion criteria included emergency procedures, planned sternotomy, and delayed HCR beyond 100 days. Propensity score matching (PSM) compared outcomes between MIDCAB-first and PCI-first strategies.</p><p><b>Results:</b> The median time interval between MIDCAB and PCI was 22 days. Early stent and graft failure rates were 2.8% and 2.2%, respectively. Kaplan–Meier estimated survival was 79.1% at 5 years, 64.2% at 10 years, 49.8% at 15 years, and 37.8% at 20 years. Freedom from repeat revascularization was 86.3% at 5 years and 73.6% at 10 years. PSM analysis showed no significant difference in 15-year survival (57.7% vs. 50.6%, <i>p</i> = 0.68) or 10-year freedom from repeat revascularization (88.9% vs. 86.1%, <i>p</i> = 0.39) between the MIDCAB-first and PCI-first groups.</p><p><b>Conclusion:</b> HCR provides durable long-term survival and revascularization outcomes, with comparable results between MIDCAB-first and PCI-first strategies. These findings support HCR as a viable alternative to conventional CABG in selected patients.</p>","PeriodicalId":15367,"journal":{"name":"Journal of Cardiac Surgery","volume":"2025 1","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jocs/3786314","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiac Surgery","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/jocs/3786314","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hybrid coronary revascularization (HCR) combines minimally invasive direct coronary artery bypass (MIDCAB) to the left anterior descending artery (LAD) with percutaneous coronary intervention (PCI) for non-LAD lesions. HCR aims to balance the durability of surgical revascularization with the reduced invasiveness of PCI. This study evaluates 20 years of HCR experience at a single center, focusing on short- and long-term clinical outcomes.

Methods: A retrospective analysis was conducted on 2969 patients who underwent MIDCAB between 1996 and 2020 at the Heart Center Leipzig. A total of 177 patients met the inclusion criteria, defined as MIDCAB followed or preceded by PCI within 100 days. Exclusion criteria included emergency procedures, planned sternotomy, and delayed HCR beyond 100 days. Propensity score matching (PSM) compared outcomes between MIDCAB-first and PCI-first strategies.

Results: The median time interval between MIDCAB and PCI was 22 days. Early stent and graft failure rates were 2.8% and 2.2%, respectively. Kaplan–Meier estimated survival was 79.1% at 5 years, 64.2% at 10 years, 49.8% at 15 years, and 37.8% at 20 years. Freedom from repeat revascularization was 86.3% at 5 years and 73.6% at 10 years. PSM analysis showed no significant difference in 15-year survival (57.7% vs. 50.6%, p = 0.68) or 10-year freedom from repeat revascularization (88.9% vs. 86.1%, p = 0.39) between the MIDCAB-first and PCI-first groups.

Conclusion: HCR provides durable long-term survival and revascularization outcomes, with comparable results between MIDCAB-first and PCI-first strategies. These findings support HCR as a viable alternative to conventional CABG in selected patients.

Abstract Image

混合冠状动脉血管重建术:从单中心经验到长期临床结果的见解
背景:混合型冠状动脉血运重建术(HCR)将微创直接冠状动脉旁路术(MIDCAB)与经皮冠状动脉介入治疗(PCI)相结合,用于治疗非前降支病变。HCR旨在平衡外科血运重建术的持久性和降低PCI的侵入性。本研究在单一中心评估了20年的HCR经验,重点关注短期和长期临床结果。方法:对1996年至2020年在莱比锡心脏中心接受MIDCAB的2969例患者进行回顾性分析。共有177例患者符合纳入标准,定义为MIDCAB之后或之前在100天内进行PCI。排除标准包括紧急手术、计划胸骨切开术和延迟HCR超过100天。倾向评分匹配(PSM)比较midcab优先和pci优先策略的结果。结果:MIDCAB与PCI的中位时间间隔为22天。早期支架和移植物失败率分别为2.8%和2.2%。Kaplan-Meier估计5年生存率为79.1%,10年生存率为64.2%,15年生存率为49.8%,20年生存率为37.8%。5年和10年再次血运重建率分别为86.3%和73.6%。PSM分析显示,MIDCAB-first组和PCI-first组的15年生存率(57.7%比50.6%,p = 0.68)和10年无重复血运重建自由(88.9%比86.1%,p = 0.39)无显著差异。结论:HCR提供了持久的长期生存和血运重建结果,midcab优先和pci优先策略的结果相当。这些发现支持HCR在特定患者中作为传统CABG的可行替代方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.90
自引率
12.50%
发文量
976
审稿时长
3-8 weeks
期刊介绍: Journal of Cardiac Surgery (JCS) is a peer-reviewed journal devoted to contemporary surgical treatment of cardiac disease. Renown for its detailed "how to" methods, JCS''s well-illustrated, concise technical articles, critical reviews and commentaries are highly valued by dedicated readers worldwide. With Editor-in-Chief Harold Lazar, MD and an internationally prominent editorial board, JCS continues its 20-year history as an important professional resource. Editorial coverage includes biologic support, mechanical cardiac assist and/or replacement and surgical techniques, and features current material on topics such as OPCAB surgery, stented and stentless valves, endovascular stent placement, atrial fibrillation, transplantation, percutaneous valve repair/replacement, left ventricular restoration surgery, immunobiology, and bridges to transplant and recovery. In addition, special sections (Images in Cardiac Surgery, Cardiac Regeneration) and historical reviews stimulate reader interest. The journal also routinely publishes proceedings of important international symposia in a timely manner.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信